Number of sites of metastasis (NSM) and progression-free survival (PFS) in patients (PTS) with melanoma treated with ipilimumab (IPI).

e20048 Background: Metastatic melanoma is associated with poor overall survival. IPI was recently approved to this scenario in first and more lines of treatment in many countries after two landmarks phase III studies. However, this drug benefits only few PTS and nowadays we don’t have predictive factors of response. Objective: To evaluate clinical and pathological data of PTS treated with IPI and to associate with survival data. Methods: Retrospective analysis of PTS treated with IPI during expanded access(EA) to this drug between 03/2011 and 10/2012. Results: Seventy PTS were treated during EA. Gender (M/F): 29/41, age (median): 58y, ECOG (0/1): 87.2%. Histology: 78.5% skin, 14.3% choroid, 4.3% mucosal melanoma, 2.9% others. Stage: 50.7% M1c, 34.8% M1a and 14.5% M1b. LDH was above the normal limit in 50% of PTS and 20% had brain metastasis. NSM: 81% £ 3 sites and 19% 4 or more sites. Fifty-six percent received 4 doses of IPI, (71.7% in second line). The main reason to discontinue therapy was progression ...